vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Palantir Technologies (PLTR). Click either name above to swap in a different company.
Palantir Technologies is the larger business by last-quarter revenue ($1.4B vs $722.5M, roughly 1.9× Amneal Pharmaceuticals, Inc.). Palantir Technologies runs the higher net margin — 43.3% vs 10.8%, a 32.5% gap on every dollar of revenue. On growth, Palantir Technologies posted the faster year-over-year revenue change (70.0% vs 3.9%). Over the past eight quarters, Palantir Technologies's revenue compounded faster (48.9% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Palantir Technologies Inc. is an American publicly traded company that develops data integration and analytics platforms enabling government agencies, militaries, and corporations to combine and analyze data from multiple sources. Its flagship products—Gotham and Foundry —connect previously siloed databases to support intelligence operations, counterterrorism analysis, law enforcement, and enterprise analytics.
AMRX vs PLTR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $1.4B |
| Net Profit | $78.0M | $608.7M |
| Gross Margin | 44.3% | 84.6% |
| Operating Margin | — | 40.9% |
| Net Margin | 10.8% | 43.3% |
| Revenue YoY | 3.9% | 70.0% |
| Net Profit YoY | 217.0% | 670.4% |
| EPS (diluted) | $0.19 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $1.4B | ||
| Q3 25 | $784.5M | $1.2B | ||
| Q2 25 | $724.5M | $1.0B | ||
| Q1 25 | $695.4M | $883.9M | ||
| Q4 24 | $730.5M | $827.5M | ||
| Q3 24 | $702.5M | $725.5M | ||
| Q2 24 | $701.8M | $678.1M |
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $608.7M | ||
| Q3 25 | $2.4M | $475.6M | ||
| Q2 25 | $22.4M | $326.7M | ||
| Q1 25 | $12.2M | $214.0M | ||
| Q4 24 | $-31.1M | $79.0M | ||
| Q3 24 | $-156.0K | $143.5M | ||
| Q2 24 | $6.0M | $134.1M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 84.6% | ||
| Q3 25 | 34.9% | 82.4% | ||
| Q2 25 | 39.5% | 80.8% | ||
| Q1 25 | 36.8% | 80.4% | ||
| Q4 24 | 36.0% | 78.9% | ||
| Q3 24 | 38.4% | 79.8% | ||
| Q2 24 | 35.6% | 81.0% |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 40.9% | ||
| Q3 25 | 9.0% | 33.3% | ||
| Q2 25 | 15.4% | 26.8% | ||
| Q1 25 | 14.4% | 19.9% | ||
| Q4 24 | 10.4% | 1.3% | ||
| Q3 24 | 12.6% | 15.6% | ||
| Q2 24 | 13.6% | 15.5% |
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 43.3% | ||
| Q3 25 | 0.3% | 40.3% | ||
| Q2 25 | 3.1% | 32.6% | ||
| Q1 25 | 1.8% | 24.2% | ||
| Q4 24 | -4.3% | 9.5% | ||
| Q3 24 | -0.0% | 19.8% | ||
| Q2 24 | 0.9% | 19.8% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.24 | ||
| Q3 25 | $0.01 | $0.18 | ||
| Q2 25 | $0.07 | $0.13 | ||
| Q1 25 | $0.04 | $0.08 | ||
| Q4 24 | $-0.10 | $0.03 | ||
| Q3 24 | $0.00 | $0.06 | ||
| Q2 24 | $0.02 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $7.4B |
| Total Assets | — | $8.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $7.2B | ||
| Q3 25 | $201.2M | $6.4B | ||
| Q2 25 | $71.5M | $6.0B | ||
| Q1 25 | $59.2M | $5.4B | ||
| Q4 24 | $110.6M | $5.2B | ||
| Q3 24 | $74.0M | $4.6B | ||
| Q2 24 | $43.8M | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $7.4B | ||
| Q3 25 | $-109.5M | $6.6B | ||
| Q2 25 | $-112.1M | $5.9B | ||
| Q1 25 | $-131.7M | $5.4B | ||
| Q4 24 | $-109.3M | $5.0B | ||
| Q3 24 | $-93.4M | $4.5B | ||
| Q2 24 | $-57.5M | $4.1B |
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $8.9B | ||
| Q3 25 | $3.6B | $8.1B | ||
| Q2 25 | $3.4B | $7.4B | ||
| Q1 25 | $3.4B | $6.7B | ||
| Q4 24 | $3.5B | $6.3B | ||
| Q3 24 | $3.5B | $5.8B | ||
| Q2 24 | $3.5B | $5.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $777.3M |
| Free Cash FlowOCF − Capex | — | $764.0M |
| FCF MarginFCF / Revenue | — | 54.3% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $777.3M | ||
| Q3 25 | $118.5M | $507.7M | ||
| Q2 25 | $83.8M | $539.3M | ||
| Q1 25 | $7.4M | $310.3M | ||
| Q4 24 | $118.1M | $460.3M | ||
| Q3 24 | $141.8M | $419.8M | ||
| Q2 24 | $39.7M | $144.2M |
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $764.0M | ||
| Q3 25 | $106.2M | $500.9M | ||
| Q2 25 | $61.0M | $531.6M | ||
| Q1 25 | $-5.8M | $304.1M | ||
| Q4 24 | $102.9M | $457.2M | ||
| Q3 24 | $124.8M | $415.8M | ||
| Q2 24 | $29.0M | $141.3M |
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 54.3% | ||
| Q3 25 | 13.5% | 42.4% | ||
| Q2 25 | 8.4% | 53.0% | ||
| Q1 25 | -0.8% | 34.4% | ||
| Q4 24 | 14.1% | 55.3% | ||
| Q3 24 | 17.8% | 57.3% | ||
| Q2 24 | 4.1% | 20.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.9% | ||
| Q3 25 | 1.6% | 0.6% | ||
| Q2 25 | 3.2% | 0.8% | ||
| Q1 25 | 1.9% | 0.7% | ||
| Q4 24 | 2.1% | 0.4% | ||
| Q3 24 | 2.4% | 0.5% | ||
| Q2 24 | 1.5% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 1.28× | ||
| Q3 25 | 50.00× | 1.07× | ||
| Q2 25 | 3.74× | 1.65× | ||
| Q1 25 | 0.61× | 1.45× | ||
| Q4 24 | — | 5.83× | ||
| Q3 24 | — | 2.92× | ||
| Q2 24 | 6.62× | 1.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
PLTR
| Geographic Concentration Risk | $1.1B | 77% |
| Other | $330.4M | 23% |
